nach oben

Journal of Neural Transmission

Erschienen in:

05.12.2019 | Neurology and Preclinical Neurological Studies - Review Article

The catecholaldehyde hypothesis: where MAO fits in

verfasst von: David S. Goldstein

Erschienen in: Journal of Neural Transmission | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Monoamine oxidase (MAO) plays a central role in the metabolism of the neurotransmitters dopamine, norepinephrine, and serotonin. This brief review focuses on 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is the immediate product of MAO acting on cytoplasmic dopamine. DOPAL is toxic; however, normally DOPAL is converted via aldehyde dehydrogenase (ALDH) to 3,4-dihydroxyphenylacetic acid (DOPAC), which rapidly exits the neurons. In addition to vesicular uptake of dopamine via the vesicular monoamine transporter (VMAT), the two-enzyme sequence of MAO and ALDH keeps cytoplasmic dopamine levels low. Dopamine oxidizes readily to form toxic products that could threaten neuronal homeostasis. The catecholaldehyde hypothesis posits that diseases featuring catecholaminergic neurodegeneration result from harmful interactions between DOPAL and the protein alpha-synuclein, a major component of Lewy bodies in diseases such as Parkinson disease, dementia with Lewy bodies, and pure autonomic failure. DOPAL potently oligomerizes alpha-synuclein, and alpha-synuclein oligomers impede vesicular functions, shifting the fate of cytoplasmic dopamine toward MAO-catalyzed formation of DOPAL—a vicious cycle. When MAO deaminates dopamine to form DOPAL, hydrogen peroxide is generated; and DOPAL, hydrogen peroxide, and divalent metal cations react to form hydroxyl radicals, which peroxidate lipid membranes. Lipid peroxidation products in turn inhibit ALDH, causing DOPAL to accumulate—another vicious cycle. MAO inhibition decreases DOPAL formation but concurrently increases the spontaneous oxidation of dopamine, potentially trading off one form of toxicity for another. These considerations rationalize a neuroprotection strategy based on concurrent treatment with an MAO inhibitor and an anti-oxidant.

Amino T, Orimo S, Takahashi A, Uchihara T, Mizusawa H (2005) Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Path 15:29–34CrossRef

Aminoff MJ, Wilcox CS (1971) Assessment of autonomic function in patients with a Parkinsonian syndrome. Br Med J 4(779):80–84CrossRef

Anderson DG, Florang VR, Schamp JH, Buettner GR, Doorn JA (2016) Antioxidant-mediated modulation of protein reactivity for 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite. Chem Res Toxicol 29(7):1098–1107. https://doi.org/10.1021/acs.chemrestox.5b00528 CrossRefPubMedPubMedCentral

Appenzeller O, Goss JE (1971) Autonomic deficits in Parkinson’s syndrome. Arch Neurol 24:50–57CrossRef

Arai K, Kato N, Kashiwado K, Hattori T (2000) Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci Lett 296:171–173CrossRef

Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol 152(4):879–884PubMedPubMedCentral

Badillo-Ramirez I, Saniger JM, Rivas-Arancibia S (2019) 5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: implications for Parkinson’s disease. Neurochem Int 129:104514. https://doi.org/10.1016/j.neuint.2019.104514 CrossRefPubMed

Banerjee K, Munshi S, Sen O, Pramanik V, Roy Mukherjee T, Chakrabarti S (2014) Dopamine cytotoxicity involves both oxidative and nonoxidative pathways in SH-SY5Y cells: potential role of alpha-synuclein overexpression and proteasomal inhibition in the etiopathogenesis of Parkinson’s disease. Parkinsons Dis 2014:878935. https://doi.org/10.1155/2014/878935 CrossRefPubMedPubMedCentral

Benarroch EE (2003) Brainstem in multiple system atrophy: clinicopathological correlations. Cell Mol Neurobiol 23(4–5):519–526CrossRef

Bisaglia M, Mammi S, Bubacco L (2007) Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 282(21):15597–15605. https://doi.org/10.1074/jbc.M610893200 CrossRefPubMed

Bisaglia M, Greggio E, Maric D, Miller DW, Cookson MR, Bubacco L (2010) Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci 11:41. https://doi.org/10.1186/1471-2202-11-41 CrossRefPubMedPubMedCentral

Bisaglia M, Greggio E, Beltramini M, Bubacco L (2013) Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson’s disease therapies. FASEB J 27(6):2101–2110. https://doi.org/10.1096/fj.12-226852 CrossRefPubMed

Bonuccelli U, Lucetti C, Del Dotto P, Ceravolo R, Gambaccini G, Bernardini S, Rossi G, Piaggesi A (2003) Orthostatic hypotension in de novo Parkinson disease. Arch Neurol 60:1400–1404CrossRef

Braak H, de Vos RA, Bohl J, Del Tredici K (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396(1):67–72CrossRef

Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, Santos DP, Blanz J, Obermaier CD, Strojny C, Savas JN, Kiskinis E, Zhuang X, Kruger R, Surmeier DJ, Krainc D (2017) Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science 357(6357):1255–1261. https://doi.org/10.1126/science.aam9080 CrossRefPubMedPubMedCentral

Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS (2003) 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson’s disease pathogenesis. Brain Res 989(2):205–213CrossRef

Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM, Lampe P, Kumar VB, Franko M, Williams EA, Zahm DS (2004) Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25(1–2):101–115. https://doi.org/10.1016/s0161-813x(03)00090-1 CrossRefPubMed

Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, O’Dell M, Li SW, Pan Y, Chung HD, Galvin JE (2008) Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 115(2):193–203. https://doi.org/10.1007/s00401-007-0303-9 CrossRefPubMed

Cai H, Liu G, Sun L, Ding J (2014) Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson’s disease. Transl Neurodegener 3:27. https://doi.org/10.1186/2047-9158-3-27 CrossRefPubMedPubMedCentral

Carlsson A, Fornstedt B (1991) Possible mechanisms underlying the special vulnerability of dopaminergic neurons. Acta Neurol Scand Suppl 136:16–18CrossRef

Casida JE, Ford B, Jinsmaa Y, Sullivan P, Cooney A, Goldstein DS (2014) Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson’s disease. Chem Res Toxicol 27(8):1359–1361. https://doi.org/10.1021/tx5002223 CrossRefPubMedPubMedCentral

Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC, Miller GW (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27(30):8138–8148. https://doi.org/10.1523/jneurosci.0319-07.2007 CrossRefPubMedPubMedCentral

Chen L, Ding Y, Cagniard B, Van Laar AD, Mortimer A, Chi W, Hastings TG, Kang UJ, Zhuang X (2008) Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28(2):425–433. https://doi.org/10.1523/JNEUROSCI.3602-07.2008 CrossRefPubMedPubMedCentral

Colzi A, d’Agostini F, Kettler R, Borroni E, Da Prada M (1990) Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J Neural Transm Suppl 32:79–84. https://doi.org/10.1007/978-3-7091-9113-2_9 CrossRefPubMed

de la Fuente-Fernandez R, Schulzer M, Mak E, Sossi V (2010) Trials of neuroprotective therapies for Parkinson’s disease: problems and limitations. Parkinsonism Relat Disord 16(6):365–369. https://doi.org/10.1016/j.parkreldis.2010.04.008 CrossRefPubMed

Demarest KT, Moore KE (1981) Type A monoamine oxidase catalyzes the intraneuronal deamination of dopamine within nigrostriatal, mesolimbic, tuberoinfundibular and tuberohypophyseal neurons in the rat. J Neural Transm 52(3):175–187. https://doi.org/10.1007/bf01249602 CrossRefPubMed

Dukes AA, Korwek KM, Hastings TG (2005) The effect of endogenous dopamine in rotenone-induced toxicity in PC12 cells. Antioxid Redox Signal 7(5–6):630–638. https://doi.org/10.1089/ars.2005.7.630 CrossRefPubMed

Dyck LE, Durden DA, Boulton AA (1993) Effects of monoamine oxidase inhibitors on the acid metabolites of some trace amines and of dopamine in the rat striatum. Biochem Pharmacol 45(6):1317–1322. https://doi.org/10.1016/0006-2952(93)90285-5 CrossRefPubMed

Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ (1986) Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 32:2030–2033CrossRef

Eisenhofer G, Aneman A, Friberg P, Hooper D, Fandriks L, Lonroth H, Hunyady B, Mezey E (1997) Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 82(11):3864–3871CrossRef

Fabbrini G, Abbruzzese G, Marconi S, Zappia M (2012) Selegiline: a reappraisal of its role in Parkinson disease. Clin Neuropharmacol 35(3):134–140. https://doi.org/10.1097/WNF.0b013e318255838b CrossRefPubMed

Fitzmaurice AG, Rhodes SL, Lulla A, Murphy NP, Lam HA, O’Donnell KC, Barnhill L, Casida JE, Cockburn M, Sagasti A, Stahl MC, Maidment NT, Ritz B, Bronstein JM (2013) Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci USA 110(2):636–641. https://doi.org/10.1073/pnas.1220399110 CrossRefPubMed

Fitzmaurice AG, Rhodes SL, Cockburn M, Ritz B, Bronstein JM (2014) Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease. Neurology 82(5):419–426. https://doi.org/10.1212/WNL.0000000000000083 CrossRefPubMedPubMedCentral

Florang VR, Rees JN, Brogden NK, Anderson DG, Hurley TD, Doorn JA (2007) Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology 28(1):76–82. https://doi.org/10.1016/j.neuro.2006.07.018 CrossRefPubMed

Follmer C, Coelho-Cerqueira E, Yatabe-Franco DY, Araujo GD, Pinheiro AS, Domont GB, Eliezer D (2015) Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of alpha-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). J Biol Chem 290(46):27660–27679. https://doi.org/10.1074/jbc.M115.686584 CrossRefPubMedPubMedCentral

Fornai F, Giorgi FS, Bassi L, Ferrucci M, Alessandri MG, Corsini GU (2000) Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment. Brain Res 861(1):126–134CrossRef

Fornstedt B, Carlsson A (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment. J Neural Transm 76(2):155–161CrossRef

Fornstedt B, Carlsson A (1991) Effects of inhibition of monoamine oxidase on the levels of 5-S-cysteinyl adducts of catechols in dopaminergic regions of the brain of the guinea pig. Neuropharmacology 30(5):463–468CrossRef

Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog-Torres K, Hubbard B, Carter P, King P, Fahn S, Gilmor M, Telang F, Shea C, Xu Y, Muench L (2015) Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology 40(3):650–657. https://doi.org/10.1038/npp.2014.214 CrossRefPubMed

Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 19(7):2424–2431CrossRef

Gainetdinov RR, Fumagalli F, Wang YM, Jones SR, Levey AI, Miller GW, Caron MG (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 70:1973–1978CrossRef

Gautam AH, Zeevalk GD (2011) Characterization of reduced and oxidized dopamine and 3,4-dihydrophenylacetic acid, on brain mitochondrial electron transport chain activities. Biochim Biophys Acta 1807(7):819–828. https://doi.org/10.1016/j.bbabio.2011.03.013 CrossRefPubMedPubMedCentral

Goldstein DS, Holmes C, Cannon RO 3rd, Eisenhofer G, Kopin IJ (1997) Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 336(10):696–702CrossRef

Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Basile MJ, Mash DC (2011) Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol 18:703–710. https://doi.org/10.1111/j.1468-1331.2010.03246.x CrossRefPubMed

Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Sullivan R, Gross DJ, Holmes C, Kopin IJ, Sharabi Y (2012) Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson’s disease. J Neurochem 123(6):932–943. https://doi.org/10.1111/j.1471-4159.2012.07924.x CrossRefPubMedPubMedCentral

Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, Mash DC, Kopin IJ, Sharabi Y (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. J Neurochem 126(5):591–603. https://doi.org/10.1111/jnc.12345 CrossRefPubMedPubMedCentral

Goldstein DS, Sullivan P, Holmes C, Miller GW, Sharabi Y, Kopin IJ (2014) A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson disease. J Neurochem 131:219–228CrossRef

Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Kopin IJ, Sharabi Y (2015a) Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson’s disease. J Neurochem 133(1):14–25. https://doi.org/10.1111/jnc.13042 CrossRefPubMedPubMedCentral

Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Sharabi Y, Mash DC (2015b) Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy. Parkinsonism Relat Disord 21(6):567–572. https://doi.org/10.1016/j.parkreldis.2015.03.006 CrossRefPubMedPubMedCentral

Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y (2016) Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells. J Pharmacol Exp Ther 356(2):484–493. https://doi.org/10.1124/jpet.115.230201 CrossRef

Goldstein DS, Jinsmaa Y, Sullivan P, Sharabi Y (2017a) N-Acetylcysteine prevents the increase in spontaneous oxidation of dopamine during monoamine oxidase inhibition in PC12 cells. Neurochem Res 42(11):3289–3295. https://doi.org/10.1007/s11064-017-2371-0 CrossRefPubMed

Goldstein DS, Sullivan P, Holmes C, Mash DC, Kopin IJ, Sharabi Y (2017b) Determinants of denervation-independent depletion of putamen dopamine in Parkinson’s disease and multiple system atrophy. Parkinsonism Relat Disord 35:88–91. https://doi.org/10.1016/j.parkreldis.2016.12.011 CrossRefPubMed

Goldstein DS, Holmes C, Lopez GJ, Wu T, Sharabi Y (2018a) Cardiac sympathetic denervation predicts PD in at-risk individuals. Parkinsonism Relat Disord 52:90–93. https://doi.org/10.1016/j.parkreldis.2017.10.003 CrossRefPubMed

Goldstein DS, Holmes C, Lopez GJ, Wu T, Sharabi Y (2018b) Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson’s disease. Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2018.02.023 CrossRefPubMedPubMedCentral

Goldstein DS, Pekker MJ, Eisenhofer G, Sharabi Y (2019) Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases. JCI Insight. https://doi.org/10.1172/jci.insight.130441 CrossRefPubMedPubMedCentral

Group PS (1996) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Ann Neurol 39:29–36CrossRef

Grunblatt E, Ruder J, Monoranu CM, Riederer P, Youdim MB, Mandel SA (2018) Differential alterations in metabolism and proteolysis-related proteins in human Parkinson’s disease substantia nigra. Neurotox Res 33(3):560–568. https://doi.org/10.1007/s12640-017-9843-5 CrossRefPubMed

Guillot TS, Miller GW (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 39(2):149–170. https://doi.org/10.1007/s12035-009-8059-y CrossRefPubMed

Hasegawa T, Matsuzaki-Kobayashi M, Takeda A, Sugeno N, Kikuchi A, Furukawa K, Perry G, Smith MA, Itoyama Y (2006) Alpha-synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson’s disease. FEBS Lett 580(8):2147–2152. https://doi.org/10.1016/j.febslet.2006.03.018 CrossRefPubMed

Hastings TG (2009) The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson’s disease. J Bioenerg Biomembr 41(6):469–472. https://doi.org/10.1007/s10863-009-9257-z CrossRefPubMed

Herrera A, Munoz P, Steinbusch HWM, Segura-Aguilar J (2017) Are dopamine oxidation metabolites involved in the loss of dopaminergic neurons in the nigrostriatal system in Parkinson’s disease? ACS Chem Neurosci 8(4):702–711. https://doi.org/10.1021/acschemneuro.7b00034 CrossRefPubMed

Huenchuguala S, Sjodin B, Mannervik B, Segura-Aguilar J (2019) Novel alpha-synuclein oligomers formed with the aminochrome-glutathione conjugate are not neurotoxic. Neurotox Res 35(2):432–440. https://doi.org/10.1007/s12640-018-9969-0 CrossRefPubMed

Isonaka R, Rosenberg AZ, Sullivan P, Corrales A, Holmes C, Sharabi Y, Goldstein DS (2019) Alpha-Synuclein deposition within sympathetic noradrenergic neurons is associated with myocardial noradrenergic deficiency in neurogenic orthostatic hypotension. Hypertension 73(4):910–918. https://doi.org/10.1161/HYPERTENSIONAHA.118.12642 CrossRefPubMedPubMedCentral

Jain S, Goldstein DS (2012) Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis 46(3):572–580. https://doi.org/10.1016/j.nbd.2011.10.025 CrossRefPubMed

Jana S, Sinha M, Chanda D, Roy T, Banerjee K, Munshi S, Patro BS, Chakrabarti S (2011a) Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson’s disease. Biochimica et Biophys Acta 1812(6):663–673. https://doi.org/10.1016/j.bbadis.2011.02.013 CrossRef

Jana S, Sinha M, Chanda D, Roy T, Banerjee K, Munshi S, Patro BS, Chakrabarti S (2011b) Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implications in dopamine cytotoxicity and pathogenesis of Parkinson’s disease. Biochim Biophys Acta 1812(6):663–673. https://doi.org/10.1016/j.bbadis.2011.02.013 CrossRefPubMed

Jinsmaa Y, Sullivan P, Gross D, Cooney A, Sharabi Y, Goldstein DS (2014) Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. Neurosci Lett 569:27–32. https://doi.org/10.1016/j.neulet.2014.03.016 CrossRefPubMedPubMedCentral

Jinsmaa Y, Sharabi Y, Sullivan P, Isonaka R, Goldstein DS (2018) 3,4-Dihydroxyphenylacetaldehyde-induced protein modifications and their mitigation by N-acetylcysteine. J Pharmacol Exp Ther 366(1):113–124. https://doi.org/10.1124/jpet.118.248492 CrossRefPubMedPubMedCentral

Jinsmaa Y, Isonaka R, Sharabi Y, Goldstein DS (2019) 3,4-Dihydroxyphenylacetaldehyde is more efficient than dopamine in oligomerizing and quinonizing alphasynuclein. J Pharmacol Exp Ther. https://doi.org/10.1124/jpet.119.262246 CrossRefPubMedPubMedCentral

Kaufmann H, Hague K, Perl D (2001) Accumulation of alpha-synuclein in autonomic nerves in pure autonomic failure. Neurology 56(7):980–981CrossRef

Kaufmann H, Norcliffe-Kaufmann L, Palma JA, Biaggioni I, Low PA, Singer W, Goldstein DS, Peltier AC, Shibao CA, Gibbons CH, Freeman R, Robertson D (2017) Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol 81(2):287–297. https://doi.org/10.1002/ana.24877 CrossRefPubMedPubMedCentral

Khan FH, Sen T, Maiti AK, Jana S, Chatterjee U, Chakrabarti S (2005) Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson’s disease. Biochim Biophys Acta 1741(1–2):65–74. https://doi.org/10.1016/j.bbadis.2005.03.013 CrossRefPubMed

Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med 318:876–880CrossRef

Kristal BS, Conway AD, Brown AM, Jain JC, Ulluci PA, Li SW, Burke WJ (2001) Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Biol Med 30(8):924–931CrossRef

Kumagae Y, Matsui Y, Iwata N (1991) Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J Pharmacol 55(1):121–128. https://doi.org/10.1254/jjp.55.121 CrossRefPubMed

Kumar VB, Hsu FF, Lakshmi VM, Gillespie KN, Burke WJ (2019) Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced alpha-synuclein aggregation and toxicity: implication for Parkinson neuroprotective therapy. Eur J Pharmacol 845:65–73. https://doi.org/10.1016/j.ejphar.2018.12.027 CrossRefPubMed

Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, Kopin IJ (2000a) Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J Neurosci Res 60(4):552–558CrossRef

Lamensdorf I, Eisenhofer G, Harvey-White J, Nechustan A, Kirk K, Kopin IJ (2000b) 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 868(2):191–201CrossRef

Lamensdorf I, Hrycyna C, He LP, Nechushtan A, Tjurmina O, Harvey-White J, Eisenhofer G, Rojas E, Kopin IJ (2000c) Acidic dopamine metabolites are actively extruded from PC12 cells by a novel sulfonylurea-sensitive transporter. Naunyn Schmiedebergs Arch Pharmacol 361(6):654–664CrossRef

Lamotte G, Holmes C, Wu T, Goldstein DS (2019) Long-term trends in myocardial sympathetic innervation and function in synucleinopathies. Parkinsonism Relat Disord 67:27–33. https://doi.org/10.1016/j.parkreldis.2019.09.014 CrossRefPubMed

Lee HJ, Baek SM, Ho DH, Suk JE, Cho ED, Lee SJ (2011) Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp Mol Med 43(4):216–222. https://doi.org/10.3858/emm.2011.43.4.026 CrossRefPubMedPubMedCentral

Leong SL, Cappai R, Barnham KJ, Pham CL (2009) Modulation of alpha-synuclein aggregation by dopamine: a review. Neurochem Res 34(10):1838–1846. https://doi.org/10.1007/s11064-009-9986-8 CrossRefPubMed

Li SW, Lin TS, Minteer S, Burke WJ (2001) 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson’s disease pathogenesis. Brain Res Mol Brain Res 93(1):1–7CrossRef

Linsenbardt AJ, Wilken GH, Westfall TC, Macarthur H (2009) Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress. Neurotoxicology 30(6):1030–1035. https://doi.org/10.1016/j.neuro.2009.07.006 CrossRefPubMedPubMedCentral

Lohr KM, Bernstein AI, Stout KA, Dunn AR, Lazo CR, Alter SP, Wang M, Li Y, Fan X, Hess EJ, Yi H, Vecchio LM, Goldstein DS, Guillot TS, Salahpour A, Miller GW (2014) Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc Natl Acad Sci USA 111(27):9977–9982. https://doi.org/10.1073/pnas.1402134111 CrossRefPubMed

Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB (2005) Gene expression profiling of sporadic Parkinson’s disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 1053:356–375CrossRef

Mattammal MB, Haring JH, Chung HD, Raghu G, Strong R (1995) An endogenous dopaminergic neurotoxin: implication for Parkinson’s disease. Neurodegeneration 4(3):271–281CrossRef

Micieli G, Martignoni E, Cavallini A, Sandrini G, Nappi G (1987) Postprandial and orthostatic hypotension in Parkinson’s disease. Neurology 37(3):386–393CrossRef

Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, Grunblatt E, Riederer P, Jacob C, Aharon-Peretz J, Bashenko Y, Youdim MB, Mandel SA (2012) A molecular signature in blood identifies early Parkinson’s disease. Molec Neurodegen 7:26. https://doi.org/10.1186/1750-1326-7-26 CrossRef

Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Cai J, Wei X, Bazzan AJ, Zhong L, Bowen B, Intenzo CM, Iacovitti L, Newberg AB (2016) N-acetyl cysteine may support dopamine neurons in Parkinson’s disease: preliminary clinical and cell line data. PLoS One 11(6):e0157602. https://doi.org/10.1371/journal.pone.0157602 CrossRefPubMedPubMedCentral

Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Bazzan AJ, Zhong L, Bowens BK, Chervoneva I, Intenzo C, Newberg AB (2019) N-acetyl cysteine is associated with dopaminergic improvement in Parkinson’s disease. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.1548 CrossRefPubMed

Montine TJ, Picklo MJ, Amarnath V, Whetsell WO Jr, Graham DG (1997) Neurotoxicity of endogenous cysteinylcatechols. Exp Neurol 148(1):26–33. https://doi.org/10.1006/exnr.1997.6662 CrossRefPubMed

Mor DE, Tsika E, Mazzulli JR, Gould NS, Kim H, Daniels MJ, Doshi S, Gupta P, Grossman JL, Tan VX, Kalb RG, Caldwell KA, Caldwell GA, Wolfe JH, Ischiropoulos H (2017) Dopamine induces soluble alpha-synuclein oligomers and nigrostriatal degeneration. Nat Neurosci 20(11):1560–1568. https://doi.org/10.1038/nn.4641 CrossRefPubMedPubMedCentral

Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62(2):218–229. https://doi.org/10.1016/j.neuron.2009.01.033 CrossRefPubMedPubMedCentral

Munoz P, Paris I, Sanders LH, Greenamyre JT, Segura-Aguilar J (2012) Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. Biochim Biophys Acta 1822(7):1125–1136. https://doi.org/10.1016/j.bbadis.2012.03.010 CrossRefPubMed

Munoz P, Cardenas S, Huenchuguala S, Briceno A, Couve E, Paris I, Segura-Aguilar J (2015) DT-diaphorase prevents aminochrome-induced alpha-synuclein oligomer formation and neurotoxicity. Toxicol Sci 145(1):37–47. https://doi.org/10.1093/toxsci/kfv016 CrossRefPubMedPubMedCentral

Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinson’s disease. Neurosci Res 29:99–111CrossRef

Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361(13):1268–1278. https://doi.org/10.1056/NEJMoa0809335 CrossRefPubMed

Orimo S, Amino T, Takahashi A, Kojo T, Uchihara T, Mori F, Wakabayashi K, Takahashi H (2006) Cardiac sympathetic denervation in Lewy body disease. Parkinsonism Relat Disord 12(Suppl 2):S99–S105CrossRef

Panneton WM, Kumar VB, Gan Q, Burke WJ, Galvin JE (2010) The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One 5(12):e15251. https://doi.org/10.1371/journal.pone.0015251 CrossRefPubMedPubMedCentral

Paris I, Lozano J, Perez-Pastene C, Munoz P, Segura-Aguilar J (2009) Molecular and neurochemical mechanisms in PD pathogenesis. Neurotox Res 16(3):271–279. https://doi.org/10.1007/s12640-009-9059-4 CrossRefPubMed

Pham CL, Leong SL, Ali FE, Kenche VB, Hill AF, Gras SL, Barnham KJ, Cappai R (2009) Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. J Mol Biol 387(3):771–785. https://doi.org/10.1016/j.jmb.2009.02.007 CrossRefPubMed

Plotegher N, Berti G, Ferrari E, Tessari I, Zanetti M, Lunelli L, Greggio E, Bisaglia M, Veronesi M, Girotto S, Dalla Serra M, Perego C, Casella L, Bubacco L (2017) DOPAL-derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Sci Rep 7:40699. https://doi.org/10.1038/srep40699 CrossRefPubMedPubMedCentral

Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047CrossRef

Rajput AH, Rozdilsky B (1976) Dysautonomia in Parkinsonism: a clinicopathological study. J Neurol Neurosurg Psychiatry 39:1092–1100CrossRef

Ritz BR, Paul KC, Bronstein JM (2016) Of pesticides and men: a California story of genes and environment in Parkinson’s disease. Curr Environ Health Rep 3(1):40–52. https://doi.org/10.1007/s40572-016-0083-2 CrossRefPubMedPubMedCentral

Saha S, Khan MAI, Mudhara D, Deep S (2018) Tuning the balance between fibrillation and oligomerization of alpha-synuclein in the presence of dopamine. ACS Omega 3(10):14213–14224. https://doi.org/10.1021/acsomega.8b00993 CrossRefPubMedPubMedCentral

Segura-Aguilar J (2017) On the role of endogenous neurotoxins and neuroprotection in Parkinson’s disease. Neural Regen Res 12(6):897–901. https://doi.org/10.4103/1673-5374.208560 CrossRefPubMedPubMedCentral

Segura-Aguilar J (2019) On the role of aminochrome in mitochondrial dysfunction and endoplasmic reticulum stress in Parkinson’s disease. Front Neurosci 13:271. https://doi.org/10.3389/fnins.2019.00271 CrossRefPubMedPubMedCentral

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840. https://doi.org/10.1038/42166 CrossRefPubMed

Staal RG, Sonsalla PK (2000) Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther 293(2):336–342PubMed

Storch A, Ott S, Hwang YI, Ortmann R, Hein A, Frenzel S, Matsubara K, Ohta S, Wolf HU, Schwarz J (2002) Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson’s disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol 63(5):909–920CrossRef

Su Y, Duan J, Ying Z, Hou Y, Zhang Y, Wang R, Deng Y (2013) Increased vulnerability of parkin knock down PC12 cells to hydrogen peroxide toxicity: the role of salsolinol and NM-salsolinol. Neuroscience 233:72–85. https://doi.org/10.1016/j.neuroscience.2012.12.045 CrossRefPubMed

Surh YJ, Kim HJ (2010) Neurotoxic effects of tetrahydroisoquinolines and underlying mechanisms. Exp Neurobiol 19(2):63–70. https://doi.org/10.5607/en.2010.19.2.63 CrossRefPubMedPubMedCentral

Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA (2011) The origins of oxidant stress in Parkinson’s disease and therapeutic strategies. Antioxid Redox Signal 14(7):1289–1301. https://doi.org/10.1089/ars.2010.3521 CrossRefPubMedPubMedCentral

Taylor TN, Alter SP, Wang M, Goldstein DS, Miller GW (2014) Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology 76 Pt A:97–105. https://doi.org/10.1016/j.neuropharm.2013.08.033 CrossRefPubMed

Thaisetthawatkul P, Boeve BF, Benarroch EE, Sandroni P, Ferman TJ, Petersen R, Low PA (2004) Autonomic dysfunction in dementia with Lewy bodies. Neurology 62(10):1804–1809. https://doi.org/10.1212/01.wnl.0000125192.69777.6d CrossRefPubMed

Vauzour D, Corona G, Spencer JP (2010) Caffeic acid, tyrosol and p-coumaric acid are potent inhibitors of 5-S-cysteinyl-dopamine induced neurotoxicity. Arch Biochem Biophys 501(1):106–111. https://doi.org/10.1016/j.abb.2010.03.016 CrossRefPubMed

Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM (2011) Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 17(10):724–729. https://doi.org/10.1016/j.parkreldis.2011.04.016 CrossRefPubMedPubMedCentral

Wachtel SR, Abercrombie ED (1994) L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63(1):108–117. https://doi.org/10.1046/j.1471-4159.1994.63010108.x CrossRefPubMed

Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249(2–3):180–182CrossRef

Ward CD (1994) Does selegiline delay progression of Parkinson’s disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 57(2):217–220CrossRef

Weingarten P, Zhou QY (2001) Protection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors. J Neurochem 77(3):776–785CrossRef

Werner-Allen JW, DuMond JF, Levine RL, Bax A (2016) Toxic dopamine metabolite DOPAL forms an unexpected dicatechol pyrrole adduct with lysines of alpha-synuclein. Angew Chem Int Ed Engl 55(26):7374–7378. https://doi.org/10.1002/anie.201600277 CrossRefPubMedPubMedCentral

Werner-Allen JW, Levine RL, Bax A (2017) Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of alpha-synuclein. Biochem Biophys Res Commun 487(2):281–286. https://doi.org/10.1016/j.bbrc.2017.04.050 CrossRefPubMedPubMedCentral

Werner-Allen JW, Monti S, DuMond JF, Levine RL, Bax A (2018) Isoindole linkages provide a pathway for DOPAL-mediated cross-linking of alpha-synuclein. Biochemistry 57(9):1462–1474. https://doi.org/10.1021/acs.biochem.7b01164 CrossRefPubMedPubMedCentral

Wey M, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, Strong R (2012) Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson’s disease. PLoS ONE 7:e31522CrossRef

Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA 108(10):4194–4199. https://doi.org/10.1073/pnas.1100976108 CrossRefPubMed

Wu YN, Johnson SW (2011) Dopamine oxidation facilitates rotenone-dependent potentiation of N-methyl-D-aspartate currents in rat substantia nigra dopamine neurons. Neuroscience 195:138–144. https://doi.org/10.1016/j.neuroscience.2011.08.041 CrossRefPubMed

Youdim MB, Riederer PF (2004) A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s disease. Neurology 63(7 Suppl 2):S32–S35. https://doi.org/10.1212/wnl.63.7_suppl_2.s32 CrossRefPubMed

Titel: The catecholaldehyde hypothesis: where MAO fits in
verfasst von: David S. Goldstein
Publikationsdatum: 05.12.2019
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 2/2020
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-019-02106-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The catecholaldehyde hypothesis: where MAO fits in

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Prof. Dr. Moussa B.H. Youdim: an appreciation on the occasion of his 80th birthday

Parkinson’s disease and iron

Ted Sourkes, Moussa Youdim and I

Correction to: The catecholaldehyde hypothesis: where MAO fits in

Hypothesis: neural mechanism of psychotherapy for the treatment of Parkinson’s disease: cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy?

6-Hydroxydopamine: a far from simple neurotoxin

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie